Erratum: Agreement between patients' self‐report and physicians' prescriptions on cardiovascular drug exposure: the PGRx database experience

Alpérovitch

Aubrun³

et al. 2014

Ann Rheum Dis

Section: Methodsmentioning

confidence: 99%

Impact of allopurinol on risk of myocardial infarction

Alpérovitch

Aubrun³

et al. 2014

Ann Rheum Dis

“…Detailed data on diabetes (type, age at diagnosis, duration, and history of antidiabetes treatments), complications (renal, vascular, ophthalmological, and neurological), and current and past All case and control subjects underwent an identical telephone interview specially developed for the PGRx research program using a proprietary methodology called progressiveassisted backward-active recall (PABAR) that has previously been validated (13,14). Patients were sent an interview guide ahead of time including a review of medications commonly used, listed by health problem category (cardiovascular, respiratory, metabolic, etc.).…”

Section: Data Collectionmentioning

confidence: 99%

“…The main strength of this study was the comprehensive procedure by which drug exposure and information on individual risk factors (24) were collected, using a methodology that has previously been used and validated (12,13 Case-control studies are mostly at risk for recall bias where the exposure of interest is more likely to be reported by patients experiencing the condition of interest (i.e., cancer). Precautions to prevent this bias included collecting medical prescriptions and records from health professionals and crossing the latter information with interviews, which gave excellent agreement for insulin use (97%).…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study

Cameron

Marty³

et al. 2013

Diabetes Care

Self Cite

OBJECTIVESeveral studies have been published in 2009 suggesting a possible association between insulin glargine and increased risk of malignancies, including breast cancer. The objective of this study was to assess the relation between the individual insulins (glargine, aspart, lispro, and human insulin) and development of breast cancer. RESEARCH DESIGN AND METHODSSeven hundred seventy-five incident cases of primary invasive or in situ carcinoma breast cancer occurring in women with diabetes from 92 centers in the U.K., Canada, and France were matched to a mean of 3.9 diabetic community control subjects (n = 3,050; recruited from 580 general practices) by country, age, recruitment date, and diabetes type and management. The main risk model was a multivariate conditional logistic regression model with case/control status as the dependent variable and individual insulin use, 8 years preceding the index date, as the independent variable, controlling for past use of any insulin, oral antidiabetes drugs, reproductive factors, lifestyle, education, hormone replacement therapy and history of contraceptive use, BMI, comorbidities, diabetes duration, and annual number of physician visits. Glargine was also compared with every other insulin by computing all ratios using the variance-covariance matrix of logistic model parameters. RESULTSAdjusted odds ratios of breast cancer for each type of insulin versus no use of that insulin were 1.04 (95% CI 0.76-1.44) for glargine, 1.23 (0.79-1.92) for lispro, 0.95 (0.64-1.40) for aspart, and 0.81 (0.55-1.20) for human insulin. Two-by-two comparisons found no difference between glargine and the different types of insulins. Insulin dosage or duration of use and tumor stage did not change the results. CONCLUSIONSThis international study found no difference in the risk of developing breast cancer in patients with diabetes among the different types of insulin with short-to midterm duration of use. Longer-term studies would be of interest.

“…The agreement between patients' reports of drug use and physicians' prescriptions has been described and published elsewhere. 22,23 For some specific vaccinations that were studied for other purposes, confirmation of vaccination was sought. Confirmation of influenza vaccination was requested and obtained from either the patient or his/her GP, for a sample of 40% of cases and controls reporting this vaccination.…”

Section: Assessment Of Vaccinationmentioning

confidence: 99%

“…In addition, all methods for the collection of cases, controls, and data were standardized and validated to reduce the potential for bias. 22,23 The greater exposure to influenza vaccines in the time window of 12 months preceding the index date in the control group was unexpected and raises the question about a possible protective effect of the vaccine. Several infections have been associated with ITP, including Helicobacter pylori, hepatitis C virus, and HIV.…”

mentioning

confidence: 99%

A case-control study to assess the risk of immune thrombocytopenia associated with vaccines

Michel

Aubrun³

et al. 2012

Blood

Self Cite

IntroductionImmune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts due to increased destruction and impaired platelet production, partially related to the presence of autoantibodies directed toward platelet-membrane antigens. 1 ITP manifestations include various degrees of cutaneous and/or mucosal purpura; life-threatening hemorrhages occur in less than 5% of adult patients. 2 Onset is frequently insidious and low platelet counts often last beyond 6 months. 3 In adults, the incidence of ITP is approximately 3.3 per 100 000 person-years. 4,5 Studies have suggested that immunizations could be involved in the development of autoimmune disorders. 6 This could be because of molecular mimicry, in which antigens of the host are recognized as being similar to antigens of the immunization, thus provoking the development of autoantibodies. 7,8 Although several populationbased studies have described an association between the measlesmumps-rubella vaccine and ITP in children, 9-12 published evidence concerning the risk associated with other vaccines or with vaccination in adults is sparse and limited to a few case reports. [13][14][15][16][17] The risk of ITP associated with adult vaccines therefore remains controversial. The objective of this prospective case-control study was to explore the incidence of ITP in relation to all vaccination in adults, with a special emphasis on vaccines against influenza (the injectable/killed type only) and diphtheria-tetanus-pertussispoliomyelitis (DTPP). Methods PatientsThis case-control study prospectively recruited consecutive patients with newly diagnosed ITP at 22 internal medicine and hematology centers in continental France and compared them with controls recruited from general practice settings. Cases and controls were recruited from the same geographically diverse areas. All participants (cases and controls) provided informed written consent to participate in the study, were 18-79 years of age, could read French, and were capable of answering questions by a The online version of this article contains a data supplement.The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked ''advertisement'' in accordance with 18 USC section 1734. For personal use only. on May 11, 2018. by guest www.bloodjournal.org From qualified telephone interviewer. Cases and controls were excluded from the study if they had a history of thrombocytopenia.The study protocol was submitted to the ethical review committee of Paris-Ile de France III (Comité de Protection des Personnes Ile de France III) and was approved by the French Data Protection Authority (Commission Nationale de l'Informatique et des Libertés). All participants signed an informed consent form in accordance with the Declaration of Helsinki. Study populationCase subjects. We conducted this study using patient data retrieved from the Pharmacoepidemiological General Research on ITP (PGRx-ITP) registry, a French...